Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the adequacy of the supply of triamcinolone hexacetonide injections (intra-articular steroid) for children and young people with rheumatoid arthritis.

We are aware of a shortage of triamcinolone hexacetonide 20 milligram/1 millilitre suspension for injection ampoules. Details of this shortage were shared with the National Health Service in June 2022. We are working closely with the sole supplier of this product to expedite resupplies, to make this important product is available again as soon as possible. We regularly review the tier, or impact categorisation, assigned to supply issues, and the tier of a supply issue does not affect the options available for management.

We understand how frustrating and distressing medicine supply issues can be. While we cannot always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise. We work with the pharmaceutical industry, NHS England, the devolved administrations, the Medicines and Healthcare products Regulatory Agency, and others operating in the supply chain to help prevent shortages, and to ensure that the risks to patients are minimised when supply issues arise. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.